Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. - Wikidata - wikimedia - TriplyDB

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

http://www.wikidata.org/entity/Q35906318

about

ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification Pathway-based classification of cancer subtypes.Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes.Biological convergence of cancer signatures Pathway analysis using random forests with bivariate node-split for survival outcomes E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα.Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.E2F1 and KIAA0191 expression predicts breast cancer patient survival Core module biomarker identification with network exploration for breast cancer metastasis.A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation.Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect.Cancer develops, progresses and responds to therapies through restricted perturbation of the protein-protein interaction network.Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.Reconstruction of transcriptional regulatory networks by stability-based network component analysis.Portraying breast cancers with long noncoding RNAs.Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.Information theoretic sub-network mining characterizes breast cancer subtypes in terms of cancer core mechanisms.Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion.Rbf1 degron dysfunction enhances cellular DNA replication p21 Restricts HIV-1 in Monocyte-Derived Dendritic Cells through the Reduction of Deoxynucleoside Triphosphate Biosynthesis and Regulation of SAMHD1 Antiviral Activity.Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect.Feature genes in metastatic breast cancer identified by MetaDE and SVM classifier methods.ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1.The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients.NEDD4-induced degradative ubiquitination of phosphatidylinositol 4-phosphate 5-kinase α and its implication in breast cancer cell proliferation.Expression patterns of E2F transcription factors and their potential prognostic roles in breast cancer.Expressions and prognostic values of the transcription factors in human breast carcinoma

P2860

Q24300315-5366E9E3-9B0D-43D6-B1E4-828D070C73E6 Q30527843-B3B0EC40-5D06-4D3D-9FDA-94A28E34ABE0 Q33331012-B201C7F5-193B-412A-83FF-C1D4EC104F81 Q33368855-590F7898-951C-4F2A-BC45-0A673F702EFF Q33394388-48D72214-C2B9-47CC-853E-0E0E2471F8D5 Q33410835-6073C737-A294-425D-BC35-D095CC7B4898 Q33581774-384208A7-F41A-486C-8326-2D1E00ABF3C8 Q33728384-131571FA-AE21-4B00-842B-E22B3DFE1B1E Q33743983-C69C6B3F-9D13-4D27-9D0D-7A3592F73124 Q33858905-6F66E9F0-AD84-440A-A53A-48CBA74BAC20 Q34132404-E801A8A3-AA35-4CCB-9519-F62D00741396 Q34266467-59E5B915-A875-4FAB-8497-959DB82E6C85 Q35065451-A319BBD4-608A-425F-AA17-A931BC7C85A8 Q35666395-FE2282DD-D6FD-4FB6-8DEB-72FDEF9CFEBE Q36424477-22F44CB1-6285-46EB-87AE-E068A0F45BD0 Q36609038-719070CD-C35C-412C-89E3-0E80DD6D3D49 Q36840512-EE60B017-B23D-4E8E-BA79-389511CF2A0C Q37230214-CC86F63C-3012-46BC-94DF-A889D4D9275B Q37344480-9D87C1F3-84C5-47F8-95E3-56D4A3E656CD Q37367871-EAF8DBFA-40B9-4532-8831-B4A89CC357AF Q39315724-9EFFB801-394C-4A37-815C-7A437376BEE5 Q39667297-AA8D402F-594A-45B8-B85E-801629912AF4 Q39971591-6FDD962D-83A3-4204-B2C8-B5FD41C330C3 Q41226375-175F0897-D3BA-44DF-89B5-CF70473CEB18 Q41933397-A6DC9568-86BA-4450-9924-FF1602AAA448 Q42421244-3F45BFE5-5B2F-4961-9A97-09165BCA319F Q50068159-BBE96AD0-1A4C-4A77-98D5-4153219BD218 Q52597050-5E3ACE12-B475-4D18-8AB5-38EEE4C0BF6E Q53266094-7BAE1273-89AB-478F-AADC-712B0A9D2896 Q54977561-B61B5AD9-C2A5-4A66-96F8-5C70831B5B2A Q55315668-E346B669-86EE-4C08-AC36-AE0B904E60E6 Q57075023-B69AFE91-A294-467C-B08E-119252D8F765

P2860

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

http://www.wikidata.org/entity/Q35906318

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@ast

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@en

type

label

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@ast

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@en

prefLabel

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@ast

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@en

P1433

Q35906318-5D13782F-0E87-4653-BB59-84748B7EDBDD

P1476

Q35906318-A8B5166A-04CB-4DC4-9B8E-56ACF56F6F88

P2093

Q35906318-01BE7250-4D8D-4FBD-8A77-4E958095C81B

Q35906318-01EDD83C-0FDA-4B59-87EA-B9578730083C

Q35906318-4441C5BE-0442-41BC-82A0-9B899C3DE0E5

Q35906318-4F5EFECF-4698-41D1-86A4-7E795F91223B

Q35906318-9D21F747-BE2A-4859-8696-037CD1745BFF

Q35906318-B051E007-130F-47F4-9BA5-B4658DA5CB3B

Q35906318-BD4FE9D6-FF1F-4544-93AD-A36307EE1263

Q35906318-C1CB49F9-016E-4F84-B854-FB1472B344A5

Q35906318-D9302B0A-61E4-4B46-8423-351F9C5A48C8

Q35906318-E8A40F7B-A912-43B8-A866-6059A58FE245

P2860

Q35906318-0D20AC60-E35C-48CF-9542-5251062FAF10

Q35906318-18BE1222-A60A-4D1F-B92D-C7BD90A74168

Q35906318-1F82311D-ADFA-4E0F-A489-C090499C41CF

Q35906318-337034E1-05E9-462C-9657-350BF6F0F821

Q35906318-41D5B48D-4C35-44DA-882B-5AFBD45B71AD

Q35906318-47BA4C15-D708-460B-8D80-A16EBFD01DD4

Q35906318-59BE0B9B-7355-4D44-9B87-57AD4C3846F5

Q35906318-647037AF-CA2B-487F-9BD5-473B7CBDAD11

Q35906318-6C86C8EC-D6AC-4679-8049-93CEE5BB195F

Q35906318-8596F5B9-178A-4EB6-8944-9A9D55340B06

P2888

Q35906318-F2065AE1-B6EA-4D8C-B8EF-86AF5D440A01

P304

Q35906318-85FBB279-F6D8-4272-99BA-82E6C895CA78

P31

Q35906318-549F116C-9EE8-49B9-8DC6-4B3B7C67B3A5

P356

Q35906318-2FBFF49D-66CA-489A-9E51-957B51DA3C8D

P433

Q35906318-10C492E9-1B11-445C-9EBC-37C3DF7D4944

P478

Q35906318-5C4F874A-F1BE-4814-9092-67E86922C6BE

P577

Q35906318-42297576-D651-4EF4-82DB-8F25DFE1DB57

P5875

Q35906318-1F5C5843-0199-467E-B403-41F8952DD839

P6179

Q35906318-EFCECD78-494F-4BB1-8FDF-2B99F3906F57

P698

Q35906318-47F48C14-6298-40E5-A92A-65FAD04F434F

P932

Q35906318-AC1D8EC0-1E6A-4A30-B7A4-67268FECF223

P356

P1433

Breast Cancer Research

P1476

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

@en

P2093

Christopher C Benz

http://www.w3.org/2001/XMLSchema#string

Frédérique Spyratos

http://www.w3.org/2001/XMLSchema#string

Holger Dieterich

http://www.w3.org/2001/XMLSchema#string

Martin Labuhn

http://www.w3.org/2001/XMLSchema#string

Mauro Delorenzi

http://www.w3.org/2001/XMLSchema#string

Patrick Urban

http://www.w3.org/2001/XMLSchema#string

Pratyaksha Wirapati

http://www.w3.org/2001/XMLSchema#string

Renata Flury

http://www.w3.org/2001/XMLSchema#string

Serenella Eppenberger-Castori

http://www.w3.org/2001/XMLSchema#string

Urs Eppenberger

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds

The Hallmarks of Cancer

Prognostic value of proliferation in invasive breast cancer: a review

Prognostic molecular markers in early breast cancer

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

A gene-expression signature as a predictor of survival in breast cancer

5-fluorouracil: mechanisms of action and clinical strategies

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

P2888

P304

R33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1681

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6301436

http://www.w3.org/2001/XMLSchema#string

P6179

1006394884

http://www.w3.org/2001/XMLSchema#string

P698

17535433

http://www.w3.org/2001/XMLSchema#string

P932

1929097

http://www.w3.org/2001/XMLSchema#string